References
- O’Shaughnessy EM, Meletiadis J, Stergiopoulou T, et al. Antifungal interactions within the triple combination of amphotericin B, caspofungin and Voriconazole against Aspergillus species. J Antimicrob Chemother. 2006;58(6):1168–1176. doi:10.1093/jac/dkl392
- Oz Y, Kiremitci A, Dag I, et al. Postantifungal effect of the combination of caspofungin with Voriconazole and amphotericin B against clinical Candida krusei isolates. Med Mycol. 2013;51(1):60–65. doi:10.3109/13693786.2012.697198
- Chandrasekar PH, Cutright JL, Manavathu EK. Efficacy of Voriconazole plus amphotericin B or micafungin in a Guinea-pig model of invasive pulmonary aspergillosis. Clin Microbiol Infect. 2004;10(10):925–928. doi:10.1111/j.1469-0691.2004.00958.x
- Silva EG, Paula CR, Dias AL, et al. Combination efficacy of Voriconazole and amphotericin B in the experimental disease in immunodeficient mice caused by fluconazole-resistant Cryptococcus neoformans. Mycopathologia. 2011;171(4):261–266. doi:10.1007/s11046-010-9375-5
- Kirkpatrick WR, Coco BJ, Patterson TF. Sequential or combination antifungal therapy with Voriconazole and liposomal amphotericin B in a guinea pig model of invasive aspergillosis. Antimicrob Agents Chemother. 2006;50(4):1567–1569. doi:10.1128/AAC.50.4.1567-1569.2006
- Verma A, Williams S, Trifilio S, et al. Successful treatment of concomitant pulmonary zygomycosis and aspergillosis with a combination of amphotericin B lipid complex, caspofungin, and Voriconazole in a patient on immunosuppression for chronic graft-versus-host disease. Bone Marrow Transplant. 2004;33(10):1065–1066. doi:10.1038/sj.bmt.1704485
- Liu JY, Liu J, Su XH, et al. Amphotericin B plus fluorocytosine combined with Voriconazole for the treatment of non-HIV and non-transplant-associated cryptococcal meningitis: a retrospective study. BMC Neurol. 2022;22(1):274. doi:10.1186/s12883-022-02803-1
- Fujioka K, Nagai T, Kinoshita Y, et al. Successful treatment with Voriconazole combined with amphotericin B-liposome for fluconazole-resistant pulmonary cryptococcosis after renal transplantation. CEN Case Rep. 2019;8(4):261–265. doi:10.1007/s13730-019-00403-6
- Chen K, Zhang X, Ke X, et al. Individualized medication of voriconazole: a practice guideline of the division of therapeutic drug monitoring, Chinese pharmacological society. Ther Drug Monit. 2018;40:663–674. doi:10.1097/FTD.0000000000000561
- Tang D, Song BL, Yan M, et al. Identifying factors affecting the pharmacokinetics of Voriconazole in patients with liver dysfunction: a population pharmacokinetic approach. Basic Clin Pharmacol Toxicol. 2019;125(1):34–43. doi:10.1111/bcpt.13208
- Hulin A, Dailly E, Le Guellec C. Level of evidence for therapeutic drug monitoring of Voriconazole. Therapie. 2011;66:109–114. doi:10.2515/therapie/2011009
- Christiansen KJ, Bernard EM, Gold JWM, et al. Distribution and activity of amphotericin B in humans. J Infect Dis. 1985;152(5):1037–1043. doi:10.1093/infdis/152.5.1037
- Massa T, Sinha DP, Frantz JD, et al. Subcronic toxicity studies of N-D-ornithyl amphotericin B methyl ester in dogs and rats. Fundam Appl Toxicol. 1985;5(4):737–753. doi:10.1016/0272-0590(85)90198-8
- Inselmann G, Schimanski A, Jahns R, et al. Liposomal amphotericin B (AmBisome) application and hepatic microsomal enzyme function in the rat. Mycoses. 1999;42(7–8):459–463. doi:10.1046/j.1439-0507.1999.00506.x